Impact of Order Set Implementation on Institutional Management of Clostridioides difficile in Adult Patients

Authors

Nicole Henry, St. John Fisher UniversityFollow
Olivia Campbell, St. John Fisher UniversityFollow
Heather Daly, University of Rochester Medical Center
Katelyn Quartuccio, University of Rochester Medical Center
Melanie Lintala, University of Rochester Medical Center

Document Type

Poster Presentation

Publication Date

12-2024

Department

Pharmacy

Abstract

In February 2022, the University of Rochester Medical Center (URMC) updated their practice guidelines, in accordance with the Infectious Diseases Society of America, to include fidaxomicin as the preferred agent in patients with initial (non-fulminant) or first recurrence of C. difficile infection (CDI).

Health system protocols were updated to include polymerase chain reaction (PCR) testing for patients with suspected CDI followed by confirmation via toxin enzyme immunoassay (EIA).

In the appropriate clinical context, PCR+/EIA+ test confirms active CDI and warrants antibiotic treatment.

PCR+/EIA- test indicates likely colonization and may preclude the need for treatment.

A CDI order set was implemented in May 2023 to facilitate guideline adherence

Comments

Poster presented at the ASHP Midyear Clinical Meeting & Exhibition in New Orleans, December 8-12, 2024

Publication Information

Henry, Nicole; Campbell, Olivia; Daly, Heather; Quartuccio, Katelyn; and Lintala, Melanie, "Impact of Order Set Implementation on Institutional Management of Clostridioides difficile in Adult Patients" (2024). Doctoral External Publications. Paper 100.
https://fisherpub.sjf.edu/doctoral_ext_pub/100

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.